Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 6Pancreatic Neoplasms 2Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × titanium silicide × Clear all
NCT03252808 2024-12-09

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Takara Bio Inc.

Phase 1 Active not recruiting
36 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00498225 2012-11-02

GEST

Taiho Pharmaceutical Co., Ltd.

Phase 3 Completed
834 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡